Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria
Status:
Recruiting
Trial end date:
2022-12-04
Target enrollment:
Participant gender:
Summary
This Phase 2a trial recruits adult patients with uncomplicated P. vivax or P. falciparum
blood-stage malaria mono-infection. The study drug SJ733 will be administered to examine its
antimalarial efficacy, safety, and tolerability. This study also evaluates whether or not a
fixed dose of the pharmacoenhancer cobicistat when given in combination with SJ733
significantly improves drug efficacy.
Phase:
Phase 2
Details
Lead Sponsor:
R. Kiplin Guy
Collaborators:
Asociacion Civil Selva Amazonica Eisai Inc. Global Health Innovative Technology Fund